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Abstract
 
K/B
 
 
 
N T cell receptor transgenic mice are a model of inflammatory arthritis, most similar to
rheumatoid arthritis, that is critically dependent on both T and B lymphocytes. Transfer of serum,
or just immunoglobulins, from arthritic K/B
 
 
 
N animals into healthy recipients provokes arthritis
efficiently, rapidly, and with high penetrance. We have explored the genetic heterogeneity in the
response to serum transfer, thereby focussing on the end-stage effector phase of arthritis, leap-
frogging the initiating events. Inbred mouse strains showed clear variability in their responses. A
few were entirely refractory to disease induction, and those which did develop disease exhibited a
range of severities. F1 analyses suggested that in most cases susceptibility was controlled in a poly-
genic additive fashion. One responder/nonresponder pair (C57Bl/6 
 
 
 
 NOD) was studied in de-
tail via a genome scan of F2 mice; supplementary information was provided by the examination
of knock-out and congenic strains. Two genomic regions that are major, additive determinants of
the rapidity and severity of K/B
 
 
 
N serum-transferred arthritis were highlighted. Concerning the
 
first region, on proximal chromosome 
 
(chr)2
 
, candidate assignment to the complement gene 
 
C5
 
was confirmed by both strain segregation analysis and functional data. Concerning the second, on
distal 
 
chr1
 
, coinciding with the 
 
Sle1
 
 locus implicated in susceptibility to lupus-like autoimmune
disease, a contribution by the 
 
fcgr2
 
 candidate gene was excluded. Two other regions, on 
 
chr12
 
 and
 
chr18
 
 may also contribute to susceptibility to serum-transferred arthritis, albeit to a more limited
degree. The contributions of these loci are additive, but gene dosage effects at the 
 
C5
 
 locus are
such that it largely dominates. The clarity of these results argues that our focus on the terminal ef-
fector phase of arthritis in the K/B
 
 
 
N model will bear fruit.
Key words: rheumatoid arthritis • animal model • genetics • complement • autoimmunity
 
Introduction
 
Somewhat surprisingly for a disease of such prevalence, the
 
etiology and pathogenesis of rheumatoid arthritis (RA)
 
*
 
 re-
main poorly understood. The diarthrodial joint lesion is
marked by hypertrophy of the synovial lining and leuko-
cyte infiltration of the synovium and the joint cavity, lead-
ing to erosion and eventual destruction of cartilage and
bone. The arthritic process clearly involves an inflamma-
tory cascade, probably pursuant to an initiating immune re-
sponse. Yet what activates the inflammatory cascade in a
joint-specific manner resulting in RA remains obscure: a
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genetic lesion? some microbial insult? a combination of the
two? Also cloudy is whether the initiating event is systemic
or joint directed.
A number of groups have attempted to harness the
power of genetic analysis to dissect the arthritic process (for
a review, see reference 1). The high prevalence of RA in
sibs or twins of affected individuals, its known familial ag-
gregation, and patterns of inheritance suggest inherited in-
fluences (2, 3), prompting the organization of several large
multicenter studies of genetic linkage in families of RA pa-
tients (4, 5). Although promising in that a number of “sug-
gestive” linkages were uncovered, these efforts failed to
demonstrate reproducible significant linkage, implying that
the underlying genetic complexity demands larger numbers
of informative families and probably some type of patient
stratification.
The identification of loci influencing RA in resemblant
animal models could prove a significant aid for the human
genetic studies. Recognizing this, multiple groups have re-
ported a number of genetic dissections of collagen-, pro-
teoglycan- or irritant-induced arthritis in rats or mice (6–
14). Here again, the picture that has emerged is one of
great complexity, with up to eight regions scoring sugges-
tively or significantly (8, 13) although, interestingly, some
of the highlighted chromosomal regions are syntenic be-
tween mice and rats (10). This complexity, as in the human
studies, probably reflects the multiple steps and molecular
pathways involved in a disease-like induced arthritis, for
example, for collagen-induced arthritis (CIA), the immune
response to injected collagen, translation of that response
into joint inflammation, and the magnitude and persistence
of the immune and inflammatory components over time.
This multiplicity of events reads out as complexity in the
inheritance patterns, lowers the signal-to-noise ratios in the
analyses, and generally hinders our progression towards
identifying heritable influences.
Genetic analyses of animal models of arthritis would no
doubt be simplified and clarified by viewing discreet disease
phases in isolation. A recently developed model of inflam-
matory arthritis, K/B
 
 
 
N TCR transgenic mice allows
such a “phase separation.” This transgene encodes a TCR
which confers reactivity to a self-peptide presented in the
context of A
 
g7
 
 class II molecules of the MHC. All K/B
 
 
 
N
animals which carry both the transgene and the stimulatory
MHC allele spontaneously develop an autoimmune disor-
der with most (although not all) of the clinical, histological,
and immunological features of human RA patients (15).
Though the murine disease appears to be exquisitely join
specific, it is provoked by T cell reactivity to glucose-6-
phosphate isomerase (GPI), an enzyme expressed in all cells
and also found circulating in the blood (16). Anti-GPI T
cell reactivity results in preferential activation of and help
to those B lymphocytes whose Ig receptors recognize GPI
and sequester the small amounts in circulation, resulting in
massive production of anti-GPI Abs, which somehow pro-
voke arthritis. Transfer of serum from arthritic K/B
 
 
 
N
mice into healthy mice routinely provokes arthritis within
days, even when the recipients are completely devoid of
 
lymphocytes (17). This serum-transfer system has obvious
attractions for genetic studies: it allows the rapid analysis of
any chosen inbred, variant, or mutant mouse strain; it is ro-
bust, with essentially 100% incidence in susceptible strains;
and it is simple, focussing on end-stage events, leap-frog-
ging the earlier autoimmune initiation phases, potentially
greatly reducing the complexity of the genetic analysis.
This report represents a broad genetic analysis of K/B
 
 
 
N
serum-tranferred arthritis. We describe genetic heterogene-
ity in the response to K/B
 
 
 
N serum in inbred mouse
strains and genetic intervals responsible for the difference
in disease manifestation shown by the C57Bl/6 (B6) and
NOD strains.
 
Materials and Methods
 
Mice.
 
For basic strain analysis, 4–5-wk-old male inbred B6,
Balb/cByJ, Balb/cJ, PL, C57BL/10, DBA/1, CBA, MRL/Mp
(MRL), NZW, C3H/He (C3H), SJL, 129/Sv, DBA/2, FvB/N,
NZB, and various F1 hybrids (Balb/c 
 
  
 
B6, B6 
 
  
 
C3H, Balb/c 
 
 
 
SJL, B6 
 
 
 
SJL, PL 
 
 
 
 SJL, and NZW 
 
 
 
 NZB) mice
 
 
 
were ob-
tained from The Jackson Laboratory. NOD/LtDOI, Balb/c 
 
 
 
PL, Balb/c 
 
 
 
 NZW, C3H 
 
 
 
 NZW, MRL 
 
  
 
Balb/c, B6 
 
 
 
NZW, NZW 
 
 
 
 SJL, C3H 
 
 
 
 SJL, and MRL 
 
 
 
 B6 were bred in
our laboratory colony. F2 cohorts were generated from both B6 
 
 
 
NOD and NOD 
 
 
 
 B6 mating pairs, and both female and male
offspring were tested at 5–6 wk of age. Fc
 
 
 
RII
 
 
 
/
 
 
 
 mice (18) on a
mixed (B6 
 
  
 
129) background and control (B6
 
 
 
129/SvImJ) F2
animals (Fc
 
 
 
RII
 
 
 
/
 
 
 
) were obtained from The Jackson Labora-
tory. B6.NODfcgr2 congenic mice (19) were bred in the animal
facility in Hopital Necker.
 
Serum Transfer Protocol and Arthritis Scoring.
 
K/B
 
 
 
N serum
pools were prepared from arthritic mice at 60 d of age. Arthritis
was induced in the diverse recipients by intraperitoneal injection
(7.5 
 
 
 
l serum per g weight) in 200 
 
 
 
l total volume at days 0 and
2. A clinical index was evaluated over time: 1 point for each af-
fected paw; and 0.5 point for a paw with only mild swelling/red-
ness or only a few digits affected. Ankle thickness was measured
by a caliper (17), ankle thickening being defined as the difference
in ankle thickness vis a vis the day 0 measure.
 
Genetic Mapping and Statistical Analysis.
 
Tail genomic DNA
was isolated from 132 (B6
 
 
 
NOD) F2 hybrids for PCR amplifi-
cation with 163 primers specific for the 
 
C5
 
 and 
 
fcgr2
 
 loci and
other microsatellite markers spanning the 19 autosomes of the
mouse genome. The 
 
C5
 
 primers, 5
 
 
 
-GGATTTTACAACAAC-
TGGAACTGC-3
 
 
 
 and 5
 
 
 
-AAGCACTAGATACTCAAACAA-
3
 
 
 
, flanking the 2-base pair (bp) deletion in the coding region of
the NOD 
 
C5
 
 gene were designed to amplify genomic fragment
from both the NOD and B6 genomes (20, 21). The 
 
fcgr2
 
 primers
were 5
 
 
 
-AGAATCTGAGAAACTTTGTT-3
 
 
 
 and 5
 
 
 
-TCGGT-
CTGTGCCCTAGTCCT-3
 
 
 
. These flank the 13-bp deletion in
the promoter region of the 
 
fcgr2b
 
 gene in NOD mice (19) and re-
sult in 187- and 200-bp fragments with NOD and B6 genomic
DNA, respectively. Amplification conditions: 92
 
 
 
C 
 
 
 
 10 s, 45
 
 
 
C 
 
 
 
30 s, and 72
 
 
 
C 
 
 
 
 30 s for 35 cycles.
 
 
 
The D1Nds8 microsatel-
lite marker was used to confirm the genetic position of the 
 
fcgr2
 
gene on chromosome 
 
(chr)1
 
 (22, 23). The other 161 primers used
for screening were selected from the MIT database (http://
carbon.wi.mit.edu:8000/cgi-bin/mouse/index#genetic), spaced
at about 10-cM intervals and efficiently discriminated the NOD
and B6 alleles. For all DnMit markers, the PCR reaction volume
was 20 
 
 
 
l containing 50 ng of genomic DNA, 0.50 mM each 
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primer, 45 mM Tris (pH 8.8), 11 mM (NH
 
4
 
)
 
2
 
SO
 
4
 
 (pH 8.8),
1.5 mM MgCl
 
2
 
, 6.7 mM 
 
 
 
-mercapto-ethanol, 4.5 mM
EDTA, 65.2 mM each dATP, dCTP, dGTP, dTTP, and 0.4 U
Taq DNA polymerase (Perkin Elmer). Thermocycling was
initiated by 4 min of denaturation and followed by a touch-
down protocol from either 60–55
 
 
 
C or 55–50
 
 
 
C. When possi-
ble, genotypes were visualized on a 4% agarose gel. For the re-
maining markers, PCR products were electrophoresed on
standard denaturing polyacrylamide gels and transferred to
positive-charged nylon membrane (Pall). The membranes
were hybridized with a primer labeled with 
 
 
 
-
 
32
 
[PdCTP] us-
ing terminal transferase (Boehringer). Genotypes were deter-
mined after autoradiography. (Discrepancies for several mark-
ers were noticed in polymorphism information provided for
the two strains by the MIT database. The full listing of mark-
ers used in this study can be consulted at http://stage.joslin.
org/research/DOI155).
Marker order and genetic distances were established with
MapMaker/Exp3.0 (24). After genetic map construction, geno-
types were verified using any of two independent criteria: viola-
tion of recombination interference (with the help of MapMan-
ager/QT2.9 [reference 25] or automatic detection of errors with
a threshold of 1% (MapMaker/Exp3.0). Quantitative trait loci
(QTLs) were detected by interval mapping with MapManager/
QTL1.1. The genome-wise significance of the findings was eval-
uated using thresholds suggested by Lander and Kruglyak (24).
Contingency table analysis was applied in parallel, bringing out
the suggestive locus on 
 
chr18
 
 in particular. Analysis of the interac-
tions between the QTLs was done both by fixing a QTL and
looking at the change in LOD scores with MapMaker/QTL3.0
and by multivariate analysis of variance (MANOVA), and by
multiple regression analysis (S-plus).
 
Results
 
Susceptibility to K/B
 
 
 
N Serum-transferred Arthritis in Inbred
Mouse Strains.
 
To evaluate the genetic heterogeneity in
response to arthritogenic serum, we transferred a fixed dose
of K/B
 
 
 
N serum into a panel of inbred mouse strains.
These included standard laboratory lines as well as lines
with a particular propensity for autoimmune or inflamma-
tory disease. 4–5-wk-old males were injected with 7.5 
 
 
 
l/g
of serum from 60-d-old arthritic K/B
 
 
 
N mice. Arthritis
was evaluated over time by visual inspection of the limbs in
order to derive a clinical index and by measurement of an-
kle thickness (15). The results are compiled in Table I, and
representative profiles for four of the strains are presented
 
in Fig. 1. Four categories of response were observed. In hy-
perreactive strains (e.g., Balb/c), inflammation was visible
already 24 h after serum injection and it rapidly attained
maximal clinical index and ankle thickening values; these
strains also exhibited the most extreme ankle swelling. Sev-
eral of the strains (e.g., DBA/1, CBA) showed the lesser
but still robust responses we previously observed with B6
mice, appearing after 3–4 d and affecting all limbs, with a
marked increase in ankle thickness. With a third group
(e.g., SJL, 129/Sv), responses were present but torpid, of-
ten affecting only one or two limbs and quite slow to reach
maximal development. Finally, a fourth group (NOD,
NZB, FvB/N, DBA/2) was completely resistant to disease
transfer.
Results from histological analyses of limbs from injected
mice largely correlated with the clinical indices (Table I).
The strongest synovitis, inflammatory infiltration of the ar-
ticular cavity, and cartilage destruction were observed in
the strains that had the greatest joint involvement and ankle
thickening. The only exceptions were the MRL/Mp and
NZW strains which showed more extensive pannus forma-
tion and cartilage erosion than one might have expected
from their clinical evaluation.
These findings pointed to significant heterogeneity
within the 
 
Mus
 
 species in susceptibility to K/B
 
 N serum-
transferred arthritis. As a first step in dissecting the genetic
basis of this heterogeneity, we generated a number of F1
hybrids between these strains and tested their response to
transfer K/B N serum (Fig. 2, Table II). Some of these
crosses were designed to evaluate trait dominance by
combining high responders with medium, low, or non-
responders. Several different outcomes were observed.
(Balb/c   NZW) F1 mice took on the rapid responsive-
ness typical of the Balb/c parent suggesting a dominant ac-
celerating Balb/c locus or loci. On the other hand, in
Balb/c crosses to B6 or MRL the more typical responsive-
ness of the latter strains won out. Finally, the (Balb/c  
SJL) F1s displayed an intermediate phenotype. In other
crosses (C3H/He   SJL or NZW   NZB), low or nonre-
sponders were combined in an attempt to reveal comple-
menting loci. But this was not observed, these F1s remain-
ing low responders; similarly, none of the F1s between
intermediate responders could reproduce the very aggres-
sive disease of the Balb/c strain.
Figure 1. Variable responses by diverse inbred
strains to K/B N serum-transferred arthritis.
Mice of each strain (4–5-wk-old males) were in-
jected with serum from arthritic K/B N animals
(7.5  l per gram body weight) on days 0 and 2.
Arthritis was evaluated by measuring “clinical in-
dex” and “ankle thickening” (see Materials and
Methods) every day until day 21. Data from repre-
sentative, multiple experiments are shown, each
curve representing an individual mouse.324 Arthritogenic Genes
No simple genetic model can account for the diversity of
phenotypes in the inbred strains and their hybrids. Several
genes and alleles must be segregating.
Phenotype Analysis in (B6   NOD) F2 Hybrids. Next,
we chose a responder/nonresponder pair for a phenotypic/
genotypic analysis in an F2 intercross, the (B6   NOD)
combination, because i) it is a strain pair that has been stud-
ied previously in the context of autoimmune diabetes and
for which reliable polymorphic microsatellite marker sets
are available; ii) disease incidence is high and reproducible
in the B6 strain, which is the prototype strain used in many
transgenic manipulations and for which genome sequence
data should soon be available; and iii) although we know
that the NOD genetic background is not absolutely re-
quired for disease development (15), the propensity of the
NOD strain to autoimmune disease might prove relevant
in the present context.
A preliminary set of 56 (B6   NOD) F2 mice was bred
and tested for response to transfer of K/B N serum. A
wide range of phenotypes was observed (Fig. 3), ranging
from a complete lack of response to full responsiveness.
There were no sex-related differences (AUCAT0-9 of
5.94   3.17 and 5.00   3.22 in males and females, respec-
tively). Analogous to the situation with CIA (26, 27), we
suspected that the locus encoding the C5 fraction of com-
plement might be involved in the differential susceptibility
of F2 mice to K/B N serum-transferred arthritis, particu-
larly since NOD mice are C5 deficient due to a 2-bp dele-
tion in the coding region of the C5 locus (21). Therefore,
we typed the F2 mice for this trait; the results presented in
Fig. 3 are partitioned according to genotype at the C5 lo-
cus. Homozygosity for the NOD-derived C5 allele (n/n)
totally prevented arthritis transfer. This finding is substanti-
ated by the strain distribution of susceptibility to K/B N
serum (Table I): all of the four nonresponder strains
(NOD, FvB/N, NZB, DBA/2) are C5 deficient (20),
while all the strains that showed some degree of respon-
siveness are C5 proficient. Also evident was a gene-dosage
effect of the B6-derived allele; disease was usually more se-
vere in b/b homozygotes than in b/n heterozygotes.
Table I. K/B N Serum-transferred Arthritis in Diverse Inbred Strains
Histological evaluation
Strain
Max. clinical 
index Day of onseta
Max. ankle 
thickening No. of mice examined Inflammation Cartilage destruction
(mm)
Balb/c 4.0 1.2 (1–2) 1.5 11 (  )(   )
C57Bl/10 3.9 1.3 (1–3) 1.4 4 (  )(  )
PL 3.8 2.0 (1–4) 1.4 8 (  )(   )
C57Bl/6 3.5 2.9 (1–6) 1.5 19 (  )(  )
DBA/1 3.5 2.8 (2–5) 1.4 4 ( )(  )
CBA 3.5 3.5 (2–5) 1.1 4 (  )(  )
MRL/Mp 2.9 3.8 (2–4) 0.9 4 (  )(    )
NZW 2.9 4.8 (1–14) 0.7 4 (  )(    )
C3H/He 2.2 6.4 (3–12) 1 5 (   )(    )
SJL 2.2 12.4 (2–28) 0.6 12 ( )(    )
129/Sv 1.6 3.5 (3–4) 0.3 4 (   )(    )
DBA/2 ND ND 0 4 ( )(  )
FvB/N ND ND 0 4 ( )(  )
NZB ND ND 0 4 ( )(  )
NOD ND ND 0 4 ( )(  )
Different strains of mice were transferred with 7.5  l per gram body weight of serum from K/B N mice on days 0 and 2. Two mice were killed at
day 7 for histology, and the others followed until days 12–28. The “day of onset” is the first day of overt disease on one limb.
aMean (range).
Figure 2. Susceptibility of F1 mice to K/B N serum-transferred arthri-
tis. (Balb/c   SJL) F1 and (B6   NOD) F1 mice as well as the parental
strains were tested by the procedure described in the legend to Fig 1. Each
panel shows data from a representative experiment of three.  , (Balb/c  
SJL) F1;  , Balb/c;  , SJL;  , (B6   NOD) F1;  , B6;  , NOD.325 Ji et al.
On the basis of these preliminary data, there being little
point in testing resistant C5n/n mice, we transferred K/B N
serum to a cohort of 132 F2 mice that had been preselected
for carrying b/b or b/n genotypes at the C5 locus. As in the
pilot group, a wide range of responses was seen. 92.4%
showed at least some disease manifestations, and 7.6% did
not. In a recent analysis of susceptibility to pristane-induced
arthritis in rats (13), it was found that different loci con-
trolled different parameters of the animals’ response: severity,
speed of onset, and chronicity behaved as independent
quantitative traits (QTs). To test whether similar differences
are found in the K/B N serum-induced disease, we con-
verted our clinical observations on the F2 recipients to sev-
eral independent QTs; DOCI, the day of onset of clinically
detectable disease, a measure of response speed; MAX-
ATMM, the maximum degree of ankle swelling, a measure
of severity; AUC0-9AT, the integral of ankle swelling up to
day 9 after transfer, a composite measure of disease rapidity
and severity; and AUC0-21CI, the integral of the clinical in-
dex up to day 21 after serum transfer, a composite measure
incorporating disease aggressiveness and persistence. (In the
K/B N serum-transfer model, disease usually wanes slowly
after 2 wk, without establishment of a chronic state).
Genetic Mapping in the (B6   NOD) Combination. Re-
sults for the 132 mice of the (B6   NOD) F2 cohort are
presented in Fig. 4 as a set of two-parameter plots correlat-
ing the various indices. Clearly, all disease parameters were
correlated, and there was no indication of genotypes pref-
erentially affecting speed or severity. This visual evaluation
was confirmed by cluster analysis and principal components
(data not shown; Statistica).
The mice were then typed for a set of 162 informative
microsatellite markers selected from our previous analyses
(28) and from the MIT database (http://carbon.wi.mit.edu:
8000/cgi-bin/mouse/index#genetic), verified for poly-
morphism between our NOD and B6 strains. These mark-
ers gave 87.5% coverage of the mouse genome based on
Table II. Responses of Diverse Strain Combinations to K/B N Serum
Combination Strain (F1)
Max. clinical 
index Day of onseta Max. ankle thickening 
(mm)
Hi   Hi Balb/c   PL 4 1 (1) 1.5
Hi   M Balb/c   NZW 4 1 (1) 1.4
Balb/c   MRL 2.8 3.5 (2–5) 1.0
Balb/c   B6 2.5 2.5 (2–3) 0.9
Hi   Lo Balb/c   SJL 2 3.7 (3–4) 0.8
PL   SJL 1.1 5.8 (3–7) 0.3
M   M B6   NZW 2.5 4 (4)  1.6
B6   MRL 1 6.5 (6–7) 0.4
M   Lo NZW  C3H 3.5 2.5 (2–3) 1.6
B6   C3H 2.5 2.5 (2–3) 0.8
NZW   SJL 2 3.5 (1–6) 1.1
B6   SJL 1.8 5 (3–7) 0.3
Lo   Lo C3H   SJL 1.3 6 (5–7) 0.1
M   Non B6   NOD 2.5 4.2 (2–7) 1.0
NZW   NZB 1 5.5 (4–7) 0.2
Different strains of mice were transferred with 7.5  l per gram body weight with serum from K/B N mice on days 0 and 2. 2–10 mice were tested
in each group. Mice were followed until day 7. In the “combination” column, Hi, M, Lo, and Non stand for high, moderate, low, and nonresponders,
respectively. The “day of onset” is the first day of overt disease in one limb.
aMean (range).
Figure 3. Responses of mice of different C5 genotypes to transfer of
K/B N serum. In this pilot experiment, 56 (B6   NOD) F2 mice were
followed by measuring ankle thickness (see Materials and Methods) after
K/B N serum transfer. The arthritis score was read out as “AUC09AT,”
the integral of ankle swelling between 0 and 9 d after transfer, a compos-
ite measure of disease rapidity and severity. Each point represents the re-
sponse of an individual mouse. Animals were also genotyped via PCR to
identify the inactivating 2-bp deletion at the C5 locus, derived from the
NOD genome; results are plotted according to the C5 genotype.326 Arthritogenic Genes
10-cM intervals, with an average spacing of 7.84 cM be-
tween markers. The marker list and full genotype data are
accessible at http://stage.joslin.org/research/DOI155.
The genotypic data were analyzed by Mapmaker/QTL.
Two major QTLs were found, and these stood out with all
QTs tested (Table III; graphic representation in Fig. 5).
One is centered at the C5 locus on chr2, confirming the
difference in distribution between b/b and b/n genotypes
seen in the preliminary study (Fig. 3). The functional C5b
allele enhances severity in a gene-dose–dependent fashion.
The other strong locus is on chr1, roughly centered around
the D1MIT33 marker (95% confidence interval 79.0–92.3
cM). Severity is associated with the NOD-derived allele,
which behaves as “partially dominant.” The NOD strain
carries a mutation in the gene encoding the inhibitory re-
ceptor for IgG, Fc RII, which prevents efficient signaling
upon Ig engagement (19). Although the fcgr2 locus ap-
peared slightly outside the peak linkage interval on the
chromosome map (Fig. 5), it was important to ascertain its
possible contribution to the phenotype. Two lines of mice
were employed to this end: i) the B6.NODfcgr2 congenic
line, which carries the NOD allele of fcgr2 on the B6 back-
ground (19); and ii) the Fc RII /  line, which harbors a
Figure 4. Correlations between different QTs. 132 (B6   NOD) F2
mice with at least one functional C5 allele from the B6 genome were in-
jected with K/B N serum. Arthritis development was read out as four
distinct QTs: MAXATMM, the maximum degree of ankle swelling, is a
measure of severity; AUC09AT, the integral of ankle swelling up to day 9
after transfer, a composite measure of disease rapidity and severity;
AUC021CI, the integral of the clinical index in the 21 d after serum
transfer, a composite measure of disease aggressiveness and persistence;
DOCI, the day of onset of clinically detectable disease, a measure of re-
sponse speed. Two-parameter representations of these traits are shown.
Each point corresponds to an individual mouse.
Table III. Mapmaker LOD Scores for Different Markers
AUC09AT MAXATMM
LOD P LOD P
D1MIT134 1.3 0.04481
D1MIT48 2.3 0.00483 2.0 0.00891
D1MIT386 2.6 0.00249 2.2 0.00580
D1MIT469 2.8 0.00169 2.5 0.00294
D1MIT89 2.7 0.00209 2.7 0.00189
D1MIT229 3.0 0.00100 3.2 0.00069
D1MIT286 3.0 0.00100 3.2 0.00069
D1MIT102 3.8 0.00018 4.2 5.7e-5
D1MIT396 3.9 0.00013 4.4 3.7e-5
D1MIT33 4.0 9.3e-5 4.5 2.8e-5
D1MIT36 3.9 0.00014 4.4 3.8e-5
FCGR2 3.5 0.00031 4.6 2.6e-5
D1MIT221 1.8 0.01497 2.4 0.00412
D2MIT2 3.6 0.00027 3.1 0.00075
D2MIT32 5.7 2.0e-6 4.6 2.4e-5
D2MIT296 7.0 9.4e-8 5.4 4.3e-6
C5 7.0 1.2e-7 5.4 4.4e-6
D2MIT297 6.1 8.7e-7 5.6 2.3e-6
D2MIT323 5.8 1.7e-6 4.3 5.4e-5
D2MIT92 3.8 0.00018 3.4 0.00038
D2MIT182 3.6 0.00023 3.3 0.00047
D2MIT44 2.4 0.00406 2.0 0.01012
D2MIT277 1.9 0.01377
D2MIT209 1.9 0.01348 1.6 0.02458
D2MIT47 1.5 0.03414 1.4 0.03987
D12MIT136 1.9 0.01180
D12MIT109 1.7 0.02220
D12MIT156 2.6 0.00250 1.8 0.01485
D12MIT158 1.8 0.01686 1.7 0.02040
D14MIT133 1.5 0.03113
D14MIT141 1.7 0.02292
D14MIT193 1.9 0.01388
D18MIT21 1.5 0.02923
D18MIT60 1.8 0.01422 2.3 0.00446
D18MIT123 1.5 0.03491 1.3 0.04897
LOD scores  3 are shown in bold type.327 Ji et al.
knockout mutation of the fcgr2 gene (18), this mutation
rendering normally resistant H-2b mice susceptible to CIA
(29). Both of these lines were tested in time-course studies,
and in response to graded doses of K/B N serum. As illus-
trated in Fig. 6, the enhanced severity imparted by the
NOD chr1 interval in F2 mice was not reproduced by the
NOD  fcgr2 congenic interval. In addition, knockout of
fcgr2 had no apparent effect on disease, neither a positive
nor a negative one. These results strongly suggest that fcgr2
is not responsible for the chr1 effect we have detected. This
analysis also puts a right boundary on the interval, which
must map to the left of the 87.9–112 cM congenic interval
in B6.NODfcgr2.
No other locus exhibited a comparable degree of linkage
in the Mapmaker/QTL analysis. Two other regions (chr12,
19–38 cM, chr18, 4–20 cM) showed marginal evidence of
linkage according to the criteria, proposed by Lander and
Kruglyak (24).
Finally, potential epistatic interactions between the loci
were sought. As graphically illustrated in Fig. 7, which
partitions animals according to C5b homo/heterozygosity
and according to the D1MIT33 marker on chr1, the C5b
locus has a dominating effect, such that the majority of
C5b/b mice, no matter the D1MIT33 status, are high re-
sponders. The impact of the chr1 region appears less obvi-
ous than in C5 heterozygotes. However, multiple regres-
Figure 5. Chromosome susceptibility plots. MAPMAKER LOD score curves from the (B6 NOD) F2 whole genome scan for chr1 and 2 (Fig. 4). For
chr1, all four traces are shown (MAPMAKER run along free, dominant, recessive, and additive models; note that significant LOD scores are obtained
with the recessive, but not the dominant, model. For chr2, only the dominant model was warranted since n/n homozygotes are not included in the anal-
ysis. The positions (mouse genome database) of several candidate genes within the interval of interest are shown.
Figure 6. Lack of influence of the fcgr2 locus on sus-
ceptibility to K/B N serum-transferred arthritis. (A)
Congenic strain analysis. (Top) B6.NODfcgr2 ( ) or
B6 ( ) mice were injected with serum from arthritic
K/B N mice, and ankle thickness was followed over
time; each line represents an individual mouse. (Bot-
tom) A group of mice was challenged with limiting
doses of serum, and the arthritis score was measured
over the next 4 d (AUC-07AT; each dot represents an
individual mouse). (B) Knockout analysis. Fcgr2-defi-
cient mice ( ) or control (B6   129) F2 mice ( ) were
treated as in A and followed for ankle swelling over
time, or in dose–response experiments, again as in A.328 Arthritogenic Genes
sion analysis did not provide support for interaction
between C5 and D1MIT33, consistent with a simple addi-
tive model.
Discussion
We have exploited the K/B N serum-transfer system to
survey and dissect genetic influences on end-stage effector
processes during the unfolding of inflammatory arthritis.
The rapid, robust, repeatable character of the K/B N se-
rum-induced disease has allowed a straightforward genetic
examination, living up to our expectations on several
counts.
First, the experimental system permitted the expedient
study of a large panel of inbred mouse strains, which is usu-
ally impossible with murine models of autoimmune disease,
for which only a limited set of strains can usually be as-
sayed. For example, the NOD strain is one obligate partner
in genetic studies on autoimmune diabetes, and experi-
ments on CIA are restricted to mice of the H-2 haplotype
that confers responsiveness to the eliciting antigen, prima-
rily H-2q (30). Precedents from the genetic analyses of au-
toimmune diabetes have underlined the importance of as-
sessing the genetic variance for a number of strains. While,
for simplicity and as a “proof of principle,” we chose to fo-
cus on one particular strain combination in this study, ex-
amination of a large sampling of genetic variance will be
required to generate a picture that can be compared with
outbred humans. Indeed, considering the extent of genetic
variability, even that focussed within the terminal phase of
disease, one cannot help being daunted by the task of ge-
netically dissecting RA in mixed human populations.
Second, the genetic influences revealed in the (B6  
NOD) combination studied here, summarized in Table III,
appear more tractable than in cases where arthritis was
induced by immunization with collagen-, proteoglycan-, or
oil-based irritants. Two loci clearly dominated, compared
with the seven linked to inflammation in proteoglycan-
induced arthritis (31), or the four determining CIA in the
(DBA/1   B10.Q) combination (10). The influence of the
QTLs in our system also seems simpler. We did not detect
separate influences on severity and kinetics, as had been re-
ported previously for CIA (13). Undoubtedly, this great
simplification results from the narrow focus of the K/B N
serum-transfer system, where genetic influences do not risk
being masked by effects on immune responsiveness. Not
surprisingly in this context, the present analysis did not re-
produce the previously reported linkage peaks on mouse
chr3, 4, 5, 6, 7, 8, 9, 10, 13, and 16 for CIA, proteoglycan-
induced arthritis, or Lyme arthritis (9, 10, 31). These might
have influenced earlier steps in the arthritic process, reflect
different underlying pathogenetic mechanisms, or be re-
stricted to the strain combinations used in these studies, all
different from (B6 NOD).
As in many previous studies, the highly susceptible par-
ent strain in our analysis did not carry susceptible alleles at
all loci. The B6 allele on chr1 dampened K/B N serum-
induced arthritis. This will no doubt prove a feature of hu-
man populations as well.
The C5 Locus. The main genetic influence detected
with the (B6   NOD) strain pair maps to the C5 region of
chr2, where the NOD-derived allele confers nonrespon-
siveness to K/B N serum (absolute in homozygotes). A
number of arguments support the assignment of this influ-
ence to the C5 gene, itself, known to be defective in the
NOD strain (21). First, there was a perfect correlation
between nonresponse and C5 deficiency in the panel of
inbred strains (Table I). In addition, in the course of an in-
depth analysis of the role of complement pathway compo-
nents in the K/B N model, we have found that C5 activ-
ity is essential for serum-transferred arthritis, completely
prevented by treatment with an anti-C5 mAb or by a
knockout mutation of the C5a receptor gene (unpublished
data). Thus, the usual criteria for confirmation of the role
of a candidate gene have been fulfilled: the presence of an
inactivating mutation in deficient individuals, demonstra-
tion of a required biological role. Finally, implication of the
C5 locus in a murine model of arthritis has precedents.
Early evidence argued for an influence on CIA (reference
32, although such a linkage was later questioned [reference
33]); but more recent genetic data have confirmed the link
(27, 34, 35), and CIA can be prevented by administration
of anti-C5 mAb (26).
Our results significantly add to the story, showing that
C5 acts at a late effector stage of arthritis and not necessarily
in the immunological phase, as might have been extrapo-
lated from the role of complement in B lymphocyte toler-
ance (36). Further, the data demonstrate a strong C5 gene-
dosage effect. This suggests that the amounts of circulating
C5 fraction may be limiting for the development of the ar-
thritic lesion. It may prove valuable to routinely measure
C5 levels and/or identify C5 genotypes in arthritis patients
in order to stratify disease phenotypes or just to monitor
disease progression.
Figure 7. Influence of the C5 locus on the rapidity/se-
verity of K/B N serum-transferred arthritis. The results
from the (B6   NOD) F2 analysis of Fig. 4 are represented
after segregating the mice into C5b/n heterozygotes (left) or
C5b/b homozygotes (right); all C5n/n mice are fully resistant
to disease and are not represented. Within these two
groups, mice of different genotypes at D1MIT33 are rep-
resented by different symbols. Note how the C5 locus
alone has a major influence on severity, such that the effect
of the D1MIT33 genotype, readily apparent in C5b/n mice,
is far less obvious in C5b/b animals.329 Ji et al.
The chr1 Region. The other major genetic influence re-
vealed by the (B6   NOD) strain combination mapped to
the distal region of chr1. Interestingly, this stretch also con-
tains the Sle1 locus mapped by Wakeland’s group (37, 38),
a locus that controls susceptibility to a systemic lupus
erythematosus-like disease in mice. Apparent concordance
between genetic intervals influencing different autoim-
mune diseases certainly has precedent (39, 40). However,
from a pathophysiological standpoint, the connection is not
so obvious. sle1 controls the loss of tolerance to chromatin,
while the effects we have mapped concern late-stage effec-
tor mechanisms. Thus, the colocalization may only be for-
tuitous. Alternatively, members of an immunologically rel-
evant multigene family could be at the root, different
members exerting divergent influences on the immune sys-
tem processes underlying autoimmunity, or the conver-
gence might reflect different consequences of the same ge-
netic event, much as mutations affecting lytic properties of
complement also influence complex organismal events such
as B cell tolerance or lupus-like autoimmunity (36, 41, 42).
The data in Fig. 6 show that chr1’s influence cannot be
attributed to the fcgr2 gene, an otherwise attractive candi-
date because of its known alteration in the NOD strain
(19), and previous implication in CIA (29). Given the
above-discussed advantages of the K/B N serum-transfer
system, narrowing down the true support interval by con-
genic construction followed by recombinant analysis should
be a fairly straightforward task.
In conclusion, the ready applicability of the K/B N se-
rum transfer model has allowed us to employ a diversity of
inbred, congenic, and knockout mouse strains to analyze
the genetics of end-stage phenomena in murine arthritis.
One locus has been identified; positional cloning of the
second should be fairly straightforward, particularly with
the forthcoming availability of mouse genome sequence.
Ultimately, this information, together with that from paral-
lel analyses under way for other strain combinations, should
greatly help in understanding aspects of human disease and
deciphering its complex genetics.
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